Thursday - October 30, 2025
Enhertu Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival vs. T-DM1 in DESTINY-Breast05 Phase III Trial in Patients With High-Risk Early Breast Cancer Following Neoadjuvant Therapy
September 30, 2025
WILMINGTON, Delaware, Sept. 30 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial in patients with high-risk early breast cancer following neoadjuvant therapy

Second positive Phase III trial of AstraZeneca and Daiichi Sa . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products